lapatinib has been researched along with elacridar in 2 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (elacridar) | Trials (elacridar) | Recent Studies (post-2010) (elacridar) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 284 | 8 | 119 |
Protein | Taxonomy | lapatinib (IC50) | elacridar (IC50) |
---|---|---|---|
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.4427 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.2852 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Grabowski, T; Grześkowiak, E; Karbownik, A; Klupczynska, A; Plewa, S; Płotek, W; Sobańska, K; Szałek, E | 1 |
2 other study(ies) available for lapatinib and elacridar
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Brain Barrier; Brain; Cerebrospinal Fluid; Lapatinib; Male; Protein Transport; Rats; Rats, Wistar; Tetrahydroisoquinolines | 2020 |